Standout Papers

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy i... 1998 2026 2007 2016 2.3k
  1. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer (2008)
    Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology
  2. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer (2007)
    Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology
  3. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (2011)
    Marianne Pavel, John D. Hainsworth et al. The Lancet
  4. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer (2010)
    Marc Peeters, Timothy Price et al. Journal of Clinical Oncology
  5. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum (1998)
    Geert D’Haens, Karel Geboes et al. Gastroenterology
  6. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab (2007)
    Wendy De Roock, Hubert Piessevaux et al. Annals of Oncology
  7. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum (1991)
    P. Rutgeerts, Marc Peeters et al. The Lancet
  8. Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resection (1995)
    Paul Rutgeerts, Martin Hiele et al. Gastroenterology
  9. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials (2017)
    Dirk Arnold, B. Lueza et al. Annals of Oncology
  10. Nonlinear normal modes, Part I: A useful framework for the structural dynamicist (2008)
    Gaëtan Kerschen, Marc Peeters et al. Mechanical Systems and Signal Processing
  11. Nonlinear normal modes, Part II: Toward a practical computation using numerical continuation techniques (2008)
    Marc Peeters, Régis Viguié et al. Mechanical Systems and Signal Processing
  12. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study (2014)
    Timothy Price, Marc Peeters et al. The Lancet Oncology
  13. Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review (2022)
    Erwin M. J. Cornips, Marc Peeters et al. Journal of bone oncology

Immediate Impact

6 by Nobel laureates 13 from Science/Nature 106 standout
Sub-graph 1 of 17

Citing Papers

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
2023 Standout
Diagnosis and Treatment of Metastatic Colorectal Cancer
2021 Standout
14 intermediate papers

Works of Marc Peeters being referenced

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
2014 Standout
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
2013
and 23 more

Author Peers

Author Last Decade Papers Cites
Marc Peeters 14744 6912 3868 5959 732 29.7k
Pierre Laurent‐Puig 16610 6925 8303 3263 533 33.8k
Luigi Terracciano 8550 4192 4278 3990 557 25.5k
Ka‐Fai To 8864 6509 7522 4080 573 34.5k
Carolyn C. Compton 17567 9491 4955 3994 313 36.4k
Kazuhiko Koike 8213 8442 4393 11053 1.0k 35.2k
Yoshihiko Maehara 13290 12048 5533 6066 1.7k 42.1k
Kelly M. McMasters 14754 2070 4425 5007 433 23.0k
Masaki Mori 11859 9375 12288 2689 1.3k 42.6k
Pan‐Chyr Yang 10256 12535 5589 4537 800 37.9k
J. Han van Krieken 12616 5063 2778 1542 378 23.1k

All Works

Loading papers...

Rankless by CCL
2026